Ronald Kaufman
Urology · Albany, NYNPI 1487734430
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Teleflex LLC at 33.1% of the total. Reporting peaked in 2019 at $55,961 and has fallen 94.5% since, to $3,062 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $883.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$57K
- SWAN Valley Medical Incorporated$42K
- Astellas Pharma US Inc$36K
- Johnson & Johnson$20K
- Neotract Inc.$8K
- Astellas Pharma Global Development$2K
- plus $7K from 20 others
Across 54 payments — averaging $4585.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$186K
- Artivion, Inc.$32K
- Procept Biorobotics Corporation$22K
- Urovant Sciences Inc$5K
- OPKO Pharmaceuticals, LLC$2K
- E.r. Squibb & Sons, L.L.C.$598
Across 3 payments — averaging $0.00 each. An ownership or investment interest held by the physician or an immediate family member.
- SWAN Valley Medical Incorporated$0
What the payments were for
- Consulting fees$64,75037%
- Speaking & faculty fees$88,73251%
- Travel & lodging$12,1497%
- Food & beverage$7,4514%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 68 | $57,351 |
| SWAN Valley Medical Incorporated | 7 | $42,340 |
| Astellas Pharma US Inc | 39 | $36,172 |
| Johnson & Johnson(2 entities) | 31 | $20,467 |
| Neotract Inc. | 6 | $8,399 |
| Astellas Pharma Global Development | 2 | $1,913 |
| Intuitive Surgical | 10 | $1,593 |
| Immunitybio, Inc. | 1 | $1,500 |
| Provepharm Inc. | 2 | $1,142 |
| Progenics Pharmaceuticals, Inc. | 2 | $253 |
| Boston Scientific | 2 | $242 |
| Bayer | 3 | $217 |
| Procept Biorobotics Corporation | 2 | $204 |
| Novartis | 3 | $177 |
| Dendreon Pharmaceuticals LLC | 2 | $162 |
| Sumitomo Pharma America, Inc. | 2 | $141 |
| Astellas Pharma Inc | 1 | $141 |
| Urogen Pharma, Inc. | 2 | $139 |
| Pfizer | 2 | $136 |
| Merck | 1 | $125 |
| Baxter Healthcare | 1 | $125 |
| Comsort, Inc | 1 | $100 |
| Ferring Pharmaceuticals Inc. | 3 | $89 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| AstraZeneca | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$35,306
- UroLift System$25,698
- XTANDI$22,692
- Erleada$19,441
- ANKTIVA$1,500
- Da Vinci Surgical System$1,210
- BLUDIGO$1,142
- PYLARIFY$253
- KEYTRUDA$225
- ORGOVYX$217
- AquaBeam Robotic System$149
- PROVENGE$148
- FLOSEAL$125
- JELMYTO$123
- RYBREVANT$123
- CARVYKTI$123
- Nubeqa$117
- Xofigo$117
- GENERAL VASCULAR INTERVENTION$115
- TALZENNA$112
How this compares
$173,182 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 32 | $35,977 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 252 | $5,865 |
| Dutasteride | 197 | $5,650 |
| Tamsulosin Hcl | 321 | $4,362 |
| Finasteride | 216 | $3,359 |
| Bicalutamide | 18 | $1,048 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $411 |
| Ciprofloxacin Hcl | 54 | $400 |
| Anastrozole | 15 | $394 |
| Terazosin Hcl | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $36,172 | $35,97732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in Albany
- Brian MurrayAlbany$130K
- Brian InouyeAlbany$57K
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.